TW202330911A - 人類誘導性控制性ｔ細胞及其製作方法 - Google Patents

人類誘導性控制性ｔ細胞及其製作方法 Download PDF

Info

Publication number
TW202330911A
TW202330911A TW111144627A TW111144627A TW202330911A TW 202330911 A TW202330911 A TW 202330911A TW 111144627 A TW111144627 A TW 111144627A TW 111144627 A TW111144627 A TW 111144627A TW 202330911 A TW202330911 A TW 202330911A
Authority
TW
Taiwan
Prior art keywords
cells
positive
cell
inducible control
cell cluster
Prior art date
Application number
TW111144627A
Other languages
English (en)
Chinese (zh)
Inventor
三上統久
坂口志文
Original Assignee
日商雷格細胞股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商雷格細胞股份有限公司 filed Critical 日商雷格細胞股份有限公司
Publication of TW202330911A publication Critical patent/TW202330911A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW111144627A 2021-11-24 2022-11-22 人類誘導性控制性ｔ細胞及其製作方法 TW202330911A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-190127 2021-11-24
JP2021190127 2021-11-24

Publications (1)

Publication Number Publication Date
TW202330911A true TW202330911A (zh) 2023-08-01

Family

ID=86539488

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111144627A TW202330911A (zh) 2021-11-24 2022-11-22 人類誘導性控制性ｔ細胞及其製作方法

Country Status (9)

Country Link
US (1) US20250018033A1 (https=)
EP (1) EP4438722A4 (https=)
JP (3) JP7572755B2 (https=)
KR (1) KR20240116751A (https=)
CN (1) CN118591619A (https=)
CA (1) CA3239019A1 (https=)
MX (1) MX2024006360A (https=)
TW (1) TW202330911A (https=)
WO (1) WO2023095801A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250352578A1 (en) * 2021-11-24 2025-11-20 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing t cell-related disorders
EP4663195A1 (en) * 2023-02-08 2025-12-17 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing pemphigus
WO2024204553A1 (ja) * 2023-03-29 2024-10-03 レグセル株式会社 ヒト誘導性制御性ｔ細胞およびその作製方法、およびｔ細胞関連疾患を治療または予防するための医薬組成物
CN116640728B (zh) * 2023-07-24 2023-10-20 呈诺再生医学科技(北京)有限公司 RO8191和AS2863619在诱导产生表达成人型β珠蛋白的脱核红细胞中的应用
JP2025064863A (ja) * 2023-10-06 2025-04-17 株式会社マイオリッジ Ｔ細胞の培養方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
US20140309224A1 (en) 2011-09-13 2014-10-16 Roninson Igor B TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
UA117342C2 (uk) 2012-02-02 2018-07-25 Сенекс Біотекнолоджи Інк. Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку
EP2888232A1 (en) 2012-08-23 2015-07-01 F. Hoffmann-La Roche AG Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
ES2698960T3 (es) 2012-10-08 2019-02-06 Merck Patent Gmbh Compuestos de 2-aminopiridina
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
JP2016501251A (ja) 2012-12-10 2016-01-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための新規二環フェニル−ピリジン／ピラジン
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014194245A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
TW201605857A (zh) 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
JP6434989B2 (ja) 2014-03-27 2018-12-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリジルピペリジン
JP6521387B2 (ja) 2014-04-18 2019-05-29 武田薬品工業株式会社 縮合複素環化合物
EP3205645B1 (en) 2014-04-18 2019-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
JP6987338B2 (ja) * 2016-08-05 2021-12-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＭＨＣＩＩ拘束性ＣＤ４＋ＦＯＸＰ３＋制御性Ｔ細胞のｅｘ ｖｉｖｏ生成及びその治療的使用
CA3051469A1 (en) * 2017-01-27 2018-08-02 Abraham J And Phyllis Katz Cord Blood Foundation T cells derived from umbilical cord blood
US11578067B2 (en) 2017-01-30 2023-02-14 Kyoto University Compound, and method for producing regulatory T cells
US20210238551A1 (en) * 2018-08-22 2021-08-05 Osaka University Method for Generating Regulatory T Cells
EP3880213A4 (en) * 2018-11-13 2022-11-23 Abraham J and Phyllis Katz Cord Blood Foundation T CELLS WITH IMPROVED MITOCHONDRIAL FUNCTION
US20220018835A1 (en) * 2018-12-07 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
CA3140904A1 (en) * 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
AU2020380072B2 (en) * 2019-11-08 2025-11-27 Good T Cells, Inc. Epitope of regulatory T cell surface antigen, and antibody specifically binding thereto
WO2021226591A1 (en) * 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
US20210374678A1 (en) 2020-05-29 2021-12-02 Delta Pds Co., Ltd. Kanban-based work processing device and work processing method
CN115768870A (zh) * 2020-06-01 2023-03-07 促进军事医学的亨利·M·杰克逊基金会公司 诱导型调节性t细胞，其生产方法及其用途
US20250352578A1 (en) * 2021-11-24 2025-11-20 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing t cell-related disorders
EP4532697A2 (en) * 2022-06-03 2025-04-09 Beam Therapeutics Inc. Modified regulatory t cells and methods of using the same
EP4596684A1 (en) * 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)

Also Published As

Publication number Publication date
CA3239019A1 (en) 2023-06-01
JP7759136B2 (ja) 2025-10-23
EP4438722A4 (en) 2025-10-22
US20250018033A1 (en) 2025-01-16
EP4438722A1 (en) 2024-10-02
MX2024006360A (es) 2024-08-19
JP7572755B2 (ja) 2024-10-24
JP2025004140A (ja) 2025-01-14
KR20240116751A (ko) 2024-07-30
WO2023095801A1 (ja) 2023-06-01
CN118591619A (zh) 2024-09-03
JP2026009980A (ja) 2026-01-21
JPWO2023095801A1 (https=) 2023-06-01

Similar Documents

Publication Publication Date Title
TW202330911A (zh) 人類誘導性控制性ｔ細胞及其製作方法
Benveniste et al. Hematopoietic stem cells engraft in mice with absolute efficiency
CN114616467B (zh) 筛选原代人类细胞中的同源t细胞和表位反应性的高通量方法
Bennstein et al. Umbilical cord blood-derived ILC1-like cells constitute a novel precursor for mature KIR+ NKG2A-NK cells
TW202334397A (zh) 用於治療或預防t細胞相關疾病之醫藥組合物
JP3968383B2 (ja) 血液細胞の新規分類法ならびにそれを利用したテイラーメード治療および予防
Tai et al. Isolation and characterization of human multiple myeloma cell enriched populations
Kurosaka et al. Comparative studies of different stromal cell microenvironments in support of human B-cell development
Souter et al. Characterization of human mucosal‐associated invariant T (MAIT) Cells
Ukena et al. Human regulatory T cells of G-CSF mobilized allogeneic stem cell donors qualify for clinical application
EP4596684A1 (en) Induced regulatory t cells containing chimeric antigen receptor (car)
JPWO2018199186A1 (ja) 造血前駆細胞マーカー
AU2011305330B2 (en) Human B1 cells and uses thereof
HK40113682A (en) Human inducibility controllable t-cell and method for preparing same
WO2021247555A1 (en) Induced regulatory t cells, methods of production, and uses thereof
Moosmann et al. TCR activation impairs CAR-T cytotoxicity against separate target cells
HK40111669A (en) Pharmaceutical composition for treating or preventing t cell-related disorders
EP4692327A1 (en) Human inducible regulatory t cells and method for producing same, and pharmaceutical composition for treating or preventing t cell-related disease
US20240060044A1 (en) A novel method of generating t cells from peripheral blood precursors and their uses thereof
HK40123332A (en) Induced regulatory t cells containing chimeric antigen receptor (car)
WO2024166969A1 (ja) 天疱瘡を治療または予防するための医薬組成物
Alekseeva et al. In Search of Adaptive-Like Features of NK Cells Co-Expressing NKG2C and NKG2A
Wang Characterization of the lympho-neutrophil/monocyte restriction process in human cells
Tan et al. Retrovirus-induced leukemia–hijack of T-cell activation mechanisms revealed by single-cell analysis